Subscribe
hailshadow-istockphoto-com
Hailshadow / iStockphoto.com
26 October 2017Americas

Public interest group challenges ‘unmerited’ Gilead patents

Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Non-profit group continues battle against Gilead patents
8 December 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.
Americas
Non-profit asks US government to take Gilead hepatitis C patent
20 March 2018   A non-profit organisation has requested that the US government take the title of a patent covering Gilead’s sofosbuvir-based hepatitis C medicine.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Non-profit group continues battle against Gilead patents
8 December 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.
Americas
Non-profit asks US government to take Gilead hepatitis C patent
20 March 2018   A non-profit organisation has requested that the US government take the title of a patent covering Gilead’s sofosbuvir-based hepatitis C medicine.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

More on this story

Americas
Non-profit group continues battle against Gilead patents
8 December 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.
Americas
Non-profit asks US government to take Gilead hepatitis C patent
20 March 2018   A non-profit organisation has requested that the US government take the title of a patent covering Gilead’s sofosbuvir-based hepatitis C medicine.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch